With earlier diagnosis, the prognosis of those with liver cancer is greatly improved. Our VeraMarker™ metabolite profiling enables early, more accurate diagnosis.
The need for improved cancer diagnostics is compelling. Yet molecular diagnostics employing DNA, RNA, and proteins have not delivered as expected with actionable clinical tests.
Matrix-Bio is seeking investor support to validate its potentially clinically superior VeraMarker™ Liver Cancer Screening test and VeraMarker™ Colon Cancer Monitoring test.